Multimodality management for barcelona clinic liver cancer stage C hepatocellular carcinoma

Chihwan Choi, Gi Hong Choi, Tae Hyun Kim, Masatoshi Tanaka, Mao Bin Meng, Jinsil Seong

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

This review summarizes the contents of a workshop on multimodality management for Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) held on July 6, 2013, under the auspices of the 4th Asia-Pacific Primary Liver Cancer Expert Meeting Scientific Advisory Committee. BCLC stage C HCC represents a varied disease spectrum and, therefore, further stratification of BCLC stage C should be explored. Although sorafenib is currently the standard treatment for BCLC stage C HCC, the survival benefits are modest and new treatment strategies are still needed. Based on the opinions of Asian experts, there are numerous alternative options aside from sorafenib for the treatment of BCLC stage C HCC, including surgical resection, hepatic arterial infusion chemotherapy, transarterial chemoembolization, and external radiotherapy. Moreover, there are several studies on the multimodality management of BCLC stage C HCC, mainly in the form of retrospective studies and a few phase I and II trials. Multimodality management with combinations of various locoregional therapies or locoregional therapies with systemic targeted therapy using sorafenib needs to be actively investigated. The Asia-Pacific clinical practice guidelines on multimodality management for BCLC stage C HCC need recommendations based on the level of evidence, the strength of the data, and the strength of recommendations of previously reported systems.

Original languageEnglish
Pages (from-to)405-416
Number of pages12
JournalLiver Cancer
Volume3
Issue number3-4
DOIs
Publication statusPublished - 2014 Apr 16

Fingerprint

Liver Neoplasms
Hepatocellular Carcinoma
Therapeutics
Expert Testimony
Advisory Committees
Practice Guidelines
Radiotherapy
Retrospective Studies
Education
Drug Therapy
Liver
sorafenib

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Oncology

Cite this

Choi, Chihwan ; Choi, Gi Hong ; Kim, Tae Hyun ; Tanaka, Masatoshi ; Meng, Mao Bin ; Seong, Jinsil. / Multimodality management for barcelona clinic liver cancer stage C hepatocellular carcinoma. In: Liver Cancer. 2014 ; Vol. 3, No. 3-4. pp. 405-416.
@article{d1b198a7e3a34eb3bc0fa9f21528144a,
title = "Multimodality management for barcelona clinic liver cancer stage C hepatocellular carcinoma",
abstract = "This review summarizes the contents of a workshop on multimodality management for Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) held on July 6, 2013, under the auspices of the 4th Asia-Pacific Primary Liver Cancer Expert Meeting Scientific Advisory Committee. BCLC stage C HCC represents a varied disease spectrum and, therefore, further stratification of BCLC stage C should be explored. Although sorafenib is currently the standard treatment for BCLC stage C HCC, the survival benefits are modest and new treatment strategies are still needed. Based on the opinions of Asian experts, there are numerous alternative options aside from sorafenib for the treatment of BCLC stage C HCC, including surgical resection, hepatic arterial infusion chemotherapy, transarterial chemoembolization, and external radiotherapy. Moreover, there are several studies on the multimodality management of BCLC stage C HCC, mainly in the form of retrospective studies and a few phase I and II trials. Multimodality management with combinations of various locoregional therapies or locoregional therapies with systemic targeted therapy using sorafenib needs to be actively investigated. The Asia-Pacific clinical practice guidelines on multimodality management for BCLC stage C HCC need recommendations based on the level of evidence, the strength of the data, and the strength of recommendations of previously reported systems.",
author = "Chihwan Choi and Choi, {Gi Hong} and Kim, {Tae Hyun} and Masatoshi Tanaka and Meng, {Mao Bin} and Jinsil Seong",
year = "2014",
month = "4",
day = "16",
doi = "10.1159/000343861",
language = "English",
volume = "3",
pages = "405--416",
journal = "Liver Cancer",
issn = "2235-1795",
publisher = "S. Karger AG",
number = "3-4",

}

Multimodality management for barcelona clinic liver cancer stage C hepatocellular carcinoma. / Choi, Chihwan; Choi, Gi Hong; Kim, Tae Hyun; Tanaka, Masatoshi; Meng, Mao Bin; Seong, Jinsil.

In: Liver Cancer, Vol. 3, No. 3-4, 16.04.2014, p. 405-416.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Multimodality management for barcelona clinic liver cancer stage C hepatocellular carcinoma

AU - Choi, Chihwan

AU - Choi, Gi Hong

AU - Kim, Tae Hyun

AU - Tanaka, Masatoshi

AU - Meng, Mao Bin

AU - Seong, Jinsil

PY - 2014/4/16

Y1 - 2014/4/16

N2 - This review summarizes the contents of a workshop on multimodality management for Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) held on July 6, 2013, under the auspices of the 4th Asia-Pacific Primary Liver Cancer Expert Meeting Scientific Advisory Committee. BCLC stage C HCC represents a varied disease spectrum and, therefore, further stratification of BCLC stage C should be explored. Although sorafenib is currently the standard treatment for BCLC stage C HCC, the survival benefits are modest and new treatment strategies are still needed. Based on the opinions of Asian experts, there are numerous alternative options aside from sorafenib for the treatment of BCLC stage C HCC, including surgical resection, hepatic arterial infusion chemotherapy, transarterial chemoembolization, and external radiotherapy. Moreover, there are several studies on the multimodality management of BCLC stage C HCC, mainly in the form of retrospective studies and a few phase I and II trials. Multimodality management with combinations of various locoregional therapies or locoregional therapies with systemic targeted therapy using sorafenib needs to be actively investigated. The Asia-Pacific clinical practice guidelines on multimodality management for BCLC stage C HCC need recommendations based on the level of evidence, the strength of the data, and the strength of recommendations of previously reported systems.

AB - This review summarizes the contents of a workshop on multimodality management for Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) held on July 6, 2013, under the auspices of the 4th Asia-Pacific Primary Liver Cancer Expert Meeting Scientific Advisory Committee. BCLC stage C HCC represents a varied disease spectrum and, therefore, further stratification of BCLC stage C should be explored. Although sorafenib is currently the standard treatment for BCLC stage C HCC, the survival benefits are modest and new treatment strategies are still needed. Based on the opinions of Asian experts, there are numerous alternative options aside from sorafenib for the treatment of BCLC stage C HCC, including surgical resection, hepatic arterial infusion chemotherapy, transarterial chemoembolization, and external radiotherapy. Moreover, there are several studies on the multimodality management of BCLC stage C HCC, mainly in the form of retrospective studies and a few phase I and II trials. Multimodality management with combinations of various locoregional therapies or locoregional therapies with systemic targeted therapy using sorafenib needs to be actively investigated. The Asia-Pacific clinical practice guidelines on multimodality management for BCLC stage C HCC need recommendations based on the level of evidence, the strength of the data, and the strength of recommendations of previously reported systems.

UR - http://www.scopus.com/inward/record.url?scp=84922102782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922102782&partnerID=8YFLogxK

U2 - 10.1159/000343861

DO - 10.1159/000343861

M3 - Review article

VL - 3

SP - 405

EP - 416

JO - Liver Cancer

JF - Liver Cancer

SN - 2235-1795

IS - 3-4

ER -